Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Japanese Yen receives support from stealth intervention risks

Japanese Yen receives support from stealth intervention risks

FXStreetFXStreet2026/07/02 05:54
By:FXStreet

USD/JPY continues its downside after pulling back from 40-year highs, trading around 162.40 during the Asian hours on Thursday. The pair loses ground as the Japanese Yen (JPY) captures support from growing trader expectations of government intervention.

According to Reuters, sources familiar with the matter indicate that Japanese officials are abandoning their traditional habit of telegraphing intervention risks. Instead, they are shifting toward a more targeted, stealth campaign designed to squeeze speculators and drive up the cost of betting against the weakened currency.

Japan’s Ministry of Finance (MOF) may step into the market abruptly to clear out speculative short positions, deliberately avoiding any public "line in the sand" exchange rate that might trigger action. Underscoring this shift, Finance Minister Satsuki Katayama reiterated warnings that authorities remain fully prepared to respond appropriately to currency market developments at any given time.

The USD/JPY pair also loses ground as the US Dollar (USD) declines following a less hawkish tone than expected from Federal Reserve (Fed) Chairman Kevin Warsh at Wednesday's ECB Forum on Central Banking. Warsh opted not to provide explicit guidance regarding the central bank's upcoming July policy decision. While he acknowledged that inflation remains too elevated and reiterated a firm commitment to the Fed's 2% target and institutional independence, his overall tone was perceived as less hawkish than anticipated.

Wednesday’s soft US economic data further cooled the hawkish sentiment surrounding the Fed outlook. June’s ADP Employment Change report showed that private payrolls grew by just 98K, missing Wall Street's 113K forecast and slowing from May's 122K increase. Additionally, the manufacturing sector showed signs of cooling as the ISM Manufacturing PMI edged lower to 53.3, missing the 54.0 consensus estimate. Traders’ attention is on the upcoming Nonfarm Payrolls (NFP) report for fresh insights into the labor market and the Fed’s policy path.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales